BioDiem
Melbourne, Australia· Est.
Australian biotech licensing LAIV influenza vaccine technology for global partners.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech licensing LAIV influenza vaccine technology for global partners.
Infectious Diseases
Technology Platform
Live Attenuated Influenza Virus (LAIV) platform enabling intranasal vaccines produced via egg‑based or cell‑based manufacturing.
Opportunities
Licensing the LAIV platform to additional emerging‑market manufacturers and advancing the cell‑based version toward regulatory approval in Europe and the US.
Risk Factors
Dependence on third‑party partners for manufacturing and regulatory approvals, and competition from other intranasal and mRNA influenza vaccines.
Competitive Landscape
Competes with established LAIV products like FluMist and newer mRNA influenza candidates; differentiation rests on intranasal delivery and flexible egg‑/cell‑based production.